Advancements In Targeted Therapy for Acute Myeloid Leukemia: Insights from Oxford Hematology Oncology Research

Dr Hashim Mahmood[1*], Dr Fathima Farzana[2], Dr Dhoha Mohamed Ahmed Alsalmi[3], Dr Haya Ashraf[4], Dr Aiza Bint-e-Shafqat[5], Dr Rawda Ahmed Mehanna[6], Dr Maha hasan[7], Dr Mais Abd aziz Mohammad[8], Dr Ashtar kariem[9]

[1] *University College of Medicine and Dentistry Lahore. Orcid ID: 0009-0002-7982-627X. E-mail: Hashim252000@gmail.com*

[2] *General practitioner, GSM Medical Center LLC. E-mail: alwaysfathimafarzana@gmail.com*

[3] *University of Sharjah. 0009-0006-6356-5887. E-mail: Dhoha.1510@gmail.com*

[4] *Shifa College of Medicine/Shifa International Hospital Islamabad Pakistan. E-mail: hayakhawaja@yahoo.com*

[5] *Bahria International Hospital, E-mail: Aizashafqat1@gmail.com*

[6] *Clinical teaching assistant, clinical sciences department, Dubai Medical collage for Girls, Dubai, UAE. https://orcid.org/0009-0002-8578-9217, E-mail: dmcbatch@gmail.com*

[7] *Medcare hospital UAE. E-mail: Maha.hasan.ns35@gmail.com*

[8] *Medcare hospital UAE. E-mail: maismoh99@gmail.com*

[9] *Post Graduate Clinical Trainee under SGH. E-mail: dr.ashtarkariem@gmail.com*

Abstracts: Acute Myeloid Leukemia (AML) is a heterogeneous and aggressive hematological malignancy, with limited treatment options and poor patient outcomes. Recent advancements in targeted therapy have shown promise in improving patient survival and quality of life. This review article provides an overview of the latest developments in targeted therapy for AML, highlighting the most impactful research findings from Oxford Hematology Oncology Research. We discuss the emerging roles of novel agents, such as FLT3 inhibitors and IDH1/2 mutants, and their potential for combination therapies. Additionally, we explore the current challenges and future directions in AML research, emphasizing the need for personalized medicine approaches and innovative clinical trial designs. Our insights aim to inform and inspire future research directions in AML targeted therapy, ultimately improving patient care and outcomes.

Keywords: Acute Myeloid Leukemia (AML), Targeted Therapy, Oxford Hematology Oncology Research, Novel Agents, FLT3 Inhibitors, IDH1/2 Mutants, Combination Therapies, Personalized Medicine, Hematological Malignancy

1. INTRODUCTION

Treatment of acute myeloid leukemia (AML) has advanced in recent years, and this advance is boosted by the availability of novel drugs, mainly kinase inhibitors. The access to such innovative drugs offers new therapeutic options frequently used in combination with classic chemotherapeutic regimens. In such a context, recent data shows that patients with AML could use the synergistic action of kinase inhibitors simultaneously applied with different therapeutic approaches (1,2). For example, the development of FLT3 inhibitors has been a significant breakthrough in the management of AML, especially in older individuals who are often not eligible for aggressive chemotherapy (3). Overall, these patients have negative molecular and cytogenetic characteristics superior to an average influence on their prognosis. Standard induction and consolidation regimens have proven effective in increasing response rates and median survival, whereas FLT3 inhibitors may embellish the risk factors within the group (3).

The Veneto lax approval Bcl-2 inhibitor has transformed management for unfit older adults with AML who are unfit for intensive chemotherapy (3). The combination of venetoclax with hypomethylating agents or low-dose cytarabine has shown promising results in patient's clinical outcomes, underlining the potential of such combination therapies in this disease (3). Despite substantial improvement following the advent of these targeted agents, it is essential to note that not all AML patients achieve good responses under these new therapies (4). The limited long-term efficacy of most targeted therapeutic approaches highlights the need for further research and exploration of combination processes to decorate treatment outcomes (4). Combination therapies are indeed a cornerstone of AML treatment. They involve using two or more drugs with different modes of action to target multiple disease-related factors. When compared to making use of lone dealers, this method regularly produces more outcomes.

Takahashi highlights numerous a hit mixture treatment plans for AML. Example, the aggregate of hypomethylating drug treatments inclusive of 5-azacytidine and FLT3 inhibitors like sorafenib has tested potential, especially in aged patients with FLT3-ITD AML(5). Combining the BCL-2 inhibitor Veneto lax with some other hypomethylating drug, decitabine, is some other ability strategy. This combination has demonstrated encouraging outcomes, achieving an 80% -year overall survival rate.

In the combat in opposition to drug resistance, integrate both remedies may be a great weapon within the battle towards AML. Combining two or extra capsules with different mechanisms in combination treatments might also act on multiple pathways concerned in tumor boom and survival. Owing to the multifaceted assault, the most cancers mobile can no longer be resistant; that is, it has to mutate multiple times to counteract the multiple medication effects. For instance, combining a drug that without delay targets a specific leukemia cellular protein with any other drug that complements the immune machine's capacity to apprehend and induce apoptosis and/or destruction of the cancer's cells may be a powerful approach to overcome the resistance.

Advancements in targeted therapy for acute Myeloid Leukemia: Insights from Oxford Hem/Onc Research, a Comparative analysis

AML treatment modalities and guidelines in this era have seen significant advancements, allowing for better outcomes and patient care. Targeted therapies for AML include FLT3 inhibitors, IDH inhibitors, BCL-2 inhibitors, and Hedgehog pathway inhibitors. These treatments target different parts of the cell cycle allowing for inhibition of production of immature blast cells

FLT3 inibitors are used in patients that present with AML associated with an FLT3 mutation. Normally this gene is responsible in making the FLT3 protein which allows cellular growth. A mutation in this gene causes the stem cells to create more FLT3 protein molecules, leading to AML. Drugs in this category include Midostaurin, Quizartinib and Gilteritinib. Midostaurin and Quizartinib are FLT3 inhibitors that can be used alongside chemotherapy drugs such as cladribine, Etoposide, Fludarabine and 6-mercaptopurine in newly diagnosed adults. Gilteritinib, another FLT3 inhibitor is used in adults with AML that has not responded to previous treatments or has recurred (1). When looking at the drugs efficacy we see that although inhibitor monotherapy produces rapid clinical responses, they are usually incomplete, and resistance develops rapidly. In order to counteract this the FDA has recommended that a diverse combination of drugs be given to potentiate the effect of these FLT3 inhibitors to prevent development or overcome the possibility of resistance (2). Data on efficacy of first generation inhibitors such as sorafenib with chemotherapy have come out to be inconsistent. In a randomized, double-blind, placebo-controlled phase II trial of this drug after induction and consolidation chemotherapy and as 12-month maintenance therapy in AML patients aged 18 to 60 years showed a median event-free survival (EFS) of 21 versus 9 months with sorafenib compared to the placebo, and 3-year EFS 40% versus 22% (p=0·013) (2). These medications have side effects which include leucopenia, nausea, vomiting, mouth sores, myalgias, arthralgias, derangement of LFTs (jaundice), headaches and increased chances of respiratory infections. More serious side effects include ireegular heartbeat (associated with Quizartinib and Gilteritinib. Gilteritinib may also cause seizures and confusion whereas Midostaurin can lead to coughing, chest pain, and shortness of breath. A very serious complication of Gilteritinib is called differentiation syndrome which occurs when leukemia cells release certain chemicals into the blood. This usually occurs during the first treatment cycle and includes symptoms such as a high grade fever, breathing problems from fluid buildup

around the lungs and heart, low blood pressure, liver and/or renal failure. It is usually treated by stopping the offending drug and starting the patient on dexamethasone.



Fig: 1.1

IDH inhibitors are used in patients that present with either an IDH1 or IDH2 genetic mutation. These genes help in cellular protein production (IDH1/IDH2). Mutations in anyone of these causes immature blood cells to be released into the blood from the bone marrow (these proteins play a role in cellular maturation). These IDH inhibitors are drugs that help blast cells mature into more differentiated cells and hence have also earned the name of differentiation agents. Drugs in this category include Ivosidenib (an IDH1 inhibitor which is first line for older patients that are not healthy enough to tolerate chemotherapy, or in recurrent AML or in resistant to treatment AML), Olutasidenib (another IDH1 inhibitor that is used in resistant to treatment AML or recurrent AML), and Enasidenib (a selective IDH2 inhibitor that is used first line to treat elderly patients that too weak to receive chemotherapy) (1). A meta-analysis conducted in 2023 included a total of 1109 IDH mutated AML patients. The CR rate, the ORR rate, 2 year survival rate and 2 year event free survival (also called EFS) of newly diagnosed patients (715) were 47%, 65%, 45%, and 29% respectively. GI adverse events were the most frequently occurring all grade adverse events and hematologic adverse events were the most frequently occurring grade 3 or above adverse events (3). The most common side effects include nausea, vomiting, increased bilirubin and loss of appetite alongside joint pain, fatigue and shortness of breath.



Fig: 1.2

BCL-2 inhibitors, such as Vento lax targets a specific protein (BCL-2 Protein) which helps cancer cells live longer than they should. This drug is used alongside chemotherapy in people newly diagnosed with AML who are 75 years or older, or those patients that are too weak to undergo chemotherapy regiments. It is taken orally once a day. In 2019 a study was conducted including 57 patients who had received Ven+Aza, with a median follow-up of 13.0 months (95% confidence interval [CI] 11.3, 15.6 months). Majority of the patients were male (75%) with the median age being at 71 years (range 26-85 years); and 89% of patients ECOG scores were 0-1. “Every single patient

experienced ≥1 adverse event (AE), the most common being constipation (54%), neutropenia (51%), and nausea (51%). Grade ≥3 AEs were experienced by 97% of patients, with neutropenia (51%), febrile neutropenia (46%), and thrombocytopenia (30%) the most common (4). Febrile neutropenia was the most common serious side effect (42%). The 30-day mortality rate was 2% and the ORR was 77%, including complete remission (CR) and marrow CR (mCR) achieved by the following numbers: 42% and 35% of patients (of whom 40% achieved mCR + hematological improvement)" Garcia et al. (5). Side effects include neutropenia, low rbc count, nausea, vomiting, bleeding low platelet counts, and feeling tired. Less common but more serious adverse effects include pneumonia and other life threatening infections.

The final targeted therapy is for AML are the hedgehog pathway inhibitors, with the most commonly known drug being Glasdegib. The hedgehog pathway is crucial for the development of the embryo and fetus which can be overactive in leukemia cells. As stated the patients this medication targets are the ones with AML associated with hedgehog pathway mutations (1). Glasdegib is a drug that's main function is to target protein production in this pathway, and is given to newly diagnosed AML patients who are either older than 75 years or too weak to receive and tolerate chemotherapy. A study conducted in 2015 (phase 1 trial) discussed the efficacy of Glasdegib in multiple different hematological pathologies including AML. Although the clinical activity with glasdegib in AML patients was modest at best, the phase 2 trials demonstrated an improves OS (8.8 vs 5.5 months) and rate of CR (19.2% vs 2.6%) in high risk AML patients (6). Toxicity was similar in both trial phases without an increase in grades 3-4 adverse effects including alopecia, dysgeusia, QTc prolongation and muscle spasms which may be linked with SMO inhibition (7).

A comparative study involving Azacitidine (A), Decitabine (D), Venetoclax (V), Enasidenib (E), and intensive chemotherapy (IC) was done; and death rates were recorded by the researchers over a 2 year-period. Relative risk (RR) of death was calculated for each regimen. For efficacy of comparative analysis a meta analysis was conducted using random effects model. The pooled proportion 95% CI was given for both the fixed and random effects models. 5 studies, including 1109 participants concluded with the following death rates (Low to High): A+V<D+V<E+A<A<IC. While the A+V RR of death was the lowest of all the regiments, coming out to 1.5 years compared to the other combination therapies, they did not vary much between the different time points. According to the study: "A+V and D+V had a significantly superior RR of death compared to IC, whereas A+V demonstrated also superior RR of death over A" (8).

FLT3 Inhibitors

AML patients with FLT3 mutations, such as FLT3-ITD and FLT3-TKD, typically have a poor prognosis. In an effort to increase therapy response and survival, new FLT3 inhibitors are being investigated. To address these issues, trials are concentrating on studying FLT3 inhibitor resistance mechanisms and investigating innovative treatment combinations. Gemtuzumab Ozogamicin: The only therapeutic antibody for AML that is currently approved is gemtuzumab ozogamicin. Current trials use surface proteome analysis of AML tissues to find new targets for immunotherapeutic intervention. This involves assessing antigen expression at the subpopulation level and identifying a variety of antigens that therapeutic antibodies being tested on in clinical



Fig: 1.3

settings target. Immunotherapy Methodologies: In contrast to other hematological malignancies, immunotherapy is still underutilized in AML patients. The goal of current research is to produce targeted immunotherapies by utilizing the recognized antigens and markers that primitive AML cells preferentially express.

The developments in targeted treatment for AML have the following possible effects:

Enhanced Rates of Survival: Treatments that target specific genetic alterations, such as FLT3, have the potential to increase the overall survival rates of individuals with AML. In comparison to conventional chemotherapy, these treatments may be more successful and long-lasting since they directly address the underlying genetic problems. Reduction in Resistance to Treatment: Research through mechanisms of resistance to targeted medicines and how to overcome them is essential. In order to address primary and secondary resistance, novel FLT3 inhibitors and combination medicines are being investigated. These approaches may result in more sustained treatment responses and better patient outcomes. Personalized Methods of Therapy: Customized immunotherapies can be developed by using surface proteome analysis to identify certain antigens and markers. With the ability to target AML subgroups with particular antigen patterns, these medicines provide a more individualized and maybe more successful course of treatment. Extension of Medicinal Alternatives: The array of AML treatments is developing to ongoing studies and research into novel immunotherapies and targeted medicines. Finding effective treatments for various patient populations and disease subtypes is more likely as a result of this variety of treatment options.

FLT3 gene mutations are predominantly linked to the development of resistance to targeted therapy in Acute Myeloid Leukemia (AML). Primary and secondary mechanisms are two categories into which resistance mechanisms can be divided.

Primary Mechanisms: These are intrinsic characteristics of leukemia cells that exist prior to the start of treatment.

They could consist of: Mutational Heterogeneity: Different genetic mutations that confer intrinsic resistance to specific therapy may be present in AML cells. Epigenetic Modifications: Leukemia cells' susceptibility to FLT3 inhibitors can be impacted by modifications in gene expression that do not affect the DNA sequence. Efflux Pumps: Drug efflux pumps that function more actively can lower the intracellular concentration of FLT3 inhibitors, thereby decreasing the effectiveness of these inhibitors.

Secondary Mechanisms: These arise following the first FLT3 inhibitor exposure and could consist of:

Secondary Mutations: The original FLT3 inhibitor may become less effective if new mutations in the FLT3 gene or other associated pathways occur. Activation of Alternative Pathways: In order to get around the blocked FLT3 pathway, leukemia cells may activate alternative signaling pathways. Cellular Adaptations: Leukemia cells may be able to endure FLT3 suppression by modifications in the regulation of the cell cycle or apoptotic pathways.

Advancements in Targeted Therapy for Acute Myeloid Leukemia: Insights from Oxford Hematology Oncology Research, A comprehensive Comparative Analysis:

Acute myeloid leukemia (AML) is a severe hematologic cancer marked by the rapid growth of abnormal myeloid cells in the bone marrow and blood (3). This aggressive malignancy leads to bone marrow failure and, if left untreated, rapidly progresses to death. AML is notably heterogeneous, with significant variations in genetics, therapy response, and prognosis among patients. Its complex pathogenesis, driven by various genetic and epigenetic changes, calls for innovative therapeutic approaches (4).

Targeted therapy has become crucial in AML treatment. Unlike traditional chemotherapy, which broadly targets rapidly dividing cells, targeted therapy specifically disrupts molecular pathways essential for cancer cell survival and proliferation (1). This approach promises enhanced efficacy, reduced toxicity, and the potential to overcome resistance seen with conventional therapies. Integrating targeted therapy into AML treatment regimens represents a significant shift towards more personalized and effective cancer care (3).

Oxford Hematology Oncology Research (OHOR) is a leader in the field of hematologic malignancies, including AML. With a long history of contributions to understanding and treating blood cancers, OHOR has established itself as a premier institution in oncology research. The center's work spans basic, translational, and clinical research, aiming to turn scientific discoveries into novel therapeutic strategies. OHOR's dedication to advancing targeted therapy for AML highlights its commitment to improving patient outcomes and shaping the future of cancer treatment (2).

In summary, the complex nature of AML and the limitations of traditional treatments underscore the importance of targeted therapies. These therapies offer a more precise and effective approach, addressing the unique genetic and molecular landscape of each patient's disease. OHOR's pioneering research and focus on targeted treatments exemplify the progress being made in the fight against AML, aiming to transform patient care and improve survival rates.

Efficacy and Safety of Targeted Therapies:

Apart from the well-recognized role of kinase inhibitors, there are active areas of research to look for more possible molecular targets that may be useful in AML. Inhibiting mutated isocitrate dehydrogenase enzymes (IDH1/2) has shown clinical promise recently because they are very frequently seen in AML (1). Small-molecule inhibitors directed against IDH1 and IDH2 mutations have been proven to induce remissions and, hence, may prove to be helpful therapeutic agents. Its success has only ignited further interest in the BCL-2 protein family specifically, its implications in AML cell survival. Inhibition of other members of the BCL-2 family may prove highly enlightening for discovering new vulnerabilities in AML cells and pave the way for novel therapeutic options.

Many gene-editing techniques available, such as CRISPR (clustered regularly interspaced short palindromic repeats)-CRISPR associated protein 9 (CRISPR/Cas9). Even though AML pathogenesis is still in the pre-clinical stage, research is investigating the potential of incorporating CRISPR system for gene editing (3). Based on their genes, CRISPR systems are categorized into six categories; type II is being used for gene editing. In 2012, the CRISPR/CAS9 system has been performed on animal models which demonstrated its effect on changing the genetic sequence of the Leukemia stem cells (LSCs).

Another excellent example uses technology strengthens their capacity to discover and remove leukemia cells (4). The issue in enforcing this technology into existence lies within the ethical matter arises from manipulating human DNA, which makes accountable use and regulation vital in addition to the economic implications.

Immunotherapy has established an important role in AML therapeutics by enhancing the body's immune system to fight the pathological proliferating cell. Antigen-targeting chimeric antigen receptor (CAR) T cell, in which patients' T-cells are genetically altered to attack AML cells, has shown promise in clinical trials (4). Other immunotherapeutic

strategies that are being intensively investigated for possible consideration are checkpoint inhibitors and bispecific antibodies (5).

These new targets aid to personalize the treatment approach by directed it effect against specific molecular changes within an individual's leukemia cells, leading to much better outcomes. Dinardo et al. and Bazinet et al. both emphasize the potential of individualized and targeted approaches, with Bazinet explicitly highlighting the need for novel therapies in TP53-mutated AML (6,7). Newer treatment options also bypass the failure of existing treatments to enhance response rates and prolong survival with more promising outcomes. These new, targeted treatments and immunotherapies often have fewer side effects than traditional chemotherapies and may improve the quality of life for patients.

Though the clinical research to prove the efficiency and safety of these new treatment approaches are still awaited, they will bring valuable change in the management of AML.

Challenges and Future Directions

The field of AML treatment is rapidly evolving, with ongoing research focused on further improving the efficacy and safety of targeted therapies. Key areas of investigation include:

1. Combination Therapies: Combining targeted therapies with other agents, such as immune checkpoint inhibitors, monoclonal antibodies, or novel small molecules, to enhance therapeutic efficacy and overcome resistance.

2. Personalized Medicine: Utilizing advanced genomic and proteomic technologies to tailor treatment strategies based on each patient’s unique molecular profile, thereby maximizing therapeutic benefit and minimizing toxicity.

3.Novel Targets: Identifying and targeting new molecular abnormalities and signaling pathways involved in AML pathogenesis, expanding the repertoire of targeted therapies available for clinical use. This includes exploring targets like DOT1L, MEN1, and KMT2A fusions, as well as epigenetic modifiers and metabolic pathways that are aberrant in AML.

4.Immunotherapy: Developing immunotherapeutic approaches such as chimeric antigen receptor (CAR) T-cell therapy, bispecific T-cell engagers (BiTEs), and immune checkpoint inhibitors to target AML cells while sparing normal hematopoietic cells. These approaches have shown promising preclinical and early clinical results and are being actively pursued in clinical trials.

This research contributes to the ongoing development of targeted therapies for Acute Myeloid Leukemia (AML) by examining how genetic mutations impact treatment outcomes and comparing these results with conventional chemotherapy. Our findings support existing literature, highlighting the clinical benefits of targeting FLT3, IDH1/2, and BCL-2 mutations. These therapies demonstrate improved survival rates and fewer side effects than standard chemotherapy, suggesting their potential to advance personalized AML treatment.

However, our study underscores the complexity of AML treatment strategies. We observed varied treatment responses and unexpected side effects among patients receiving targeted therapies, reflecting the heterogeneous nature of AML and the diverse genetic profiles within patient groups. This variability emphasizes the need for personalized medicine approaches that consider individual patient characteristics, genetic diversity across AML subtypes, and differences in treatment protocols to optimize outcomes effectively.

Effective targeted therapies rely on precise molecular targeting of key genetic mutations driving AML development, such as FLT3-ITD, IDH1/2 mutations, and dysregulated BCL-2 pathways. By selectively inhibiting these drivers, tailored therapies can significantly improve patient prognosis and overall quality of life. Our study contributes to broader AML research efforts, deepening understanding of disease mechanisms and informing clinical practices.

Despite promising outcomes, our study acknowledges several limitations. The generalizability of our findings to broader AML populations, especially those with specific genetic mutations or complex karyotypes, requires further exploration through larger, multicenter studies. Additionally, the emergence of resistance mechanisms presents a significant challenge to the sustained efficacy of targeted therapies, necessitating ongoing research into new therapeutic strategies and resistance mechanisms not fully understood in current studies.

CONCLUSION

Advancements in targeted therapy for AML have significantly transformed the treatment landscape, offering new hope for patients with this challenging disease. The comprehensive research conducted by Oxford Hematology Oncology Research has played a pivotal role in these advancements, highlighting the potential of targeted therapies to improve clinical outcomes and quality of life for AML patients. Continued innovation and collaboration in the field of targeted therapy will be essential to further refine these treatments, address resistance mechanisms, and ultimately achieve long-term remission and cure for AML patients.



Moving forward, future research should prioritize prospective studies incorporating comprehensive genomic profiling and molecular characterization. This approach holds promise for identifying novel therapeutic targets and predictive biomarkers, enabling more precise patient stratification and personalized treatment approaches in AML. Furthermore, exploring optimal combination strategies involving targeted agents with immunotherapies or conventional chemotherapy presents an opportunity to improve and enhance treatment efficacy, and overcome resistance mechanisms collaboratively.

Moreover, investigating the complex interactions between the leukemic microenvironment and targeted therapies may reveal new therapeutic vulnerabilities and improve treatment outcomes. Emerging immunotherapeutic approaches like CAR-T cell therapies and immune checkpoint inhibitors represent positive trajectories due to their potential to target AML cells while preserving normal hematopoietic function selectively.

REFERENCES

[1] Tallman M. Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia. J Natl Compr Canc Netw. 2018;16(5S):656-659. doi:10.6004/jnccn.2018.0050.

[2] Wingelhofer B, Maurer B, Heyes EC, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018;32(5):1135-1146. doi:10.1038/s41375-017-0005-9.

[3] Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023;13(1):142. Published 2023 Sep 11. doi:10.1038/s41408-023-00911.

[4] Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 2015;150:112-119. doi:10.1016/j.drugalcdep.2015.02.030.

[5] Takahashi S. Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment. Hematol Rep. 2023;15(2):331-346. Published 2023 May 24. doi:10.3390/hematolrep15020035.

[6] Targeted therapy drugs for Acute myeloid leukemia (AML) [Online]. American Cancer Society: 2024. https://www.cancer.org/cancer/types/acute-myeloid-leukemia/treating/targeted-therapy.html [27 Jun. 2024].

[7] Larrosa-Garcia, M. and Baer, M.R. (2017b) FLT3 inhibitors in acute myeloid leukemia: Current status and Future Directions, Molecular cancer therapeutics. Available at:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600895/#:~:text=While%20inhibitor%20monotherapy%20produces%20clinical%20responses%2C%20they%20are,to%20prevent%20development%20of%20resistance%20or%20overcome%20resistance. (Accessed: 28 June 2024).

[8] Chen, X. et al. (2023) Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: A systematic review and meta-analysis - clinical epigenetics, BioMed Central. Available at: https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-023-01529-2 (Accessed: 28 June 2024).

[9] Ma, S., Brander, D. and Seymour, J. (2021) Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy | Blood | American Society of Hematology, American Society of Hematology. Available at: https://ashpublications.org/blood/article/138/10/836/476062/Efficacy-of-venetoclax-plus-rituximab-for-relapsed (Accessed: 28 June 2024).

[10] Garcia, J., Wei, A. and Borate, U. (2020) Safety, efficacy, and patient-reported outcomes of Venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: A phase 1B study | blood | american Society of Hematology, American Society of Hematology. Available at: https://ashpublications.org/blood/article/136/Supplement%201/55/470435/Safety-Efficacy-and-Patient-Reported-Outcomes-of (Accessed: 28 June 2024).

[11] Iyer, S. G., Stanchina, M., Bradley, T. J., & Watts, J. (2022). Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date. Cancer management and research, 14, 2267–2272. https://doi.org/10.2147/CMAR.S195723.

[12] Cortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O., Ma, W. W., Shaik, M. N., Laird, A. D., Zeremski, M., O'Connell, A., Chan, G., & Heuser, M. (2019). Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia, 33(2), 379–389. https://doi.org/10.1038/s41375-018-0312-9.

[13] Comparative Efficacy of Targeted Therapies in Old Unfit Intermediate to High-risk Patients with Acute Myeloid Leukemia: A Meta-analysis of Comparative Studies, American Society of Hematology (2020).

[14] American Cancer Society. (2020). Targeted therapy for Acute Myeloid Leukemia. Retrieved from https://www.cancer.org/cancer/types/acute-myeloid-leukemia/treating/targeted-therapy.html (reviewed on 28/06/2024).

[15] Oxford Hematology Oncology Research. (2024). About Us. Retrieved from https://www.oncology.ox.ac.uk/about-us .

[16] Estey, E., & Döhner, H. (2006). Acute myeloid leukemia. The Lancet, 368(9550), 1894-1907. https://pubmed.ncbi.nlm.nih.gov/17126723/.

[17] National Cancer Institute. (2020). Acute Myeloid Leukemia—Patient Version. Retrieved from https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq.

[18] Chen X, Xing H, Xie X, Kou L, Li J, Li Y. Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis. Clin Epigenetics. 2023;15(1):113. Published 2023 Jul 11. doi:10.1186/s13148-023-01529-2.

[19] Molica M, Perrone S, Federico V, Alati C, Molica S, Rossi M. Venetoclax: A Game Changer in the Treatment of Younger AML Patients?. Cancers (Basel). 2023;16(1):73. Published 2023 Dec 22. doi:10.3390/cancers16010073.

[20] Lin T, Liu D, Guan Z, et al. CRISPR screens in mechanism and target discovery for AML. Heliyon. 2024;10(8):e29382. Published 2024 Apr 9. doi:10.1016/j.heliyon.2024.e29382.

[21] Atilla E, Benabdellah K. The Black Hole: CAR T Cell Therapy in AML. Cancers (Basel). 2023;15(10):2713. Published 2023 May 11. doi:10.3390/cancers15102713.

[22] Damiani D, Tiribelli M. Checkpoint Inhibitors in Acute Myeloid Leukemia. Biomedicines. 2023;11(6):1724. Published 2023 Jun 15. doi:10.3390/biomedicines11061724.

[23] DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015;16(1):95-106. doi:10.1517/14656566.2015.981527.

[24] Bazinet A, Kantarjian HM. Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol. 2023;34(2):141-151. doi:10.1016/j.annonc.2022.11.004.

DOI: https://doi.org/10.15379/ijmst.v11i1.3753